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Summary. Background and Objective. Studies on decompressive craniectomy (DCE) after a 
malignant middle cerebral artery (MCA) stroke in selected population show an increased prob-
ability of survival without increasing the number of very severely disabled. Cerebral infarct volume 
(CIV) as a triage criterion for performing surgery has not been discussed in literature. The aim of 
this study was to investigate the value of CIV and initial National Institutes of Health Stroke Scale 
(NIHHS) and Glasgow Coma Scale (GCS) scores as possible triage criteria in the surgical treatment 
of patients with “malignant” MCA stroke. 
Material and Methods. According to the study protocol, 28 patients with a malignant MCA 
stroke were included and analyzed prospectively. The patients were randomly divided either into the 
DCE plus best medical treatment (BMT) group or BMT alone group. CIV and NIHHS and GCS 
scores were measured at time of enrollment in every case. Clinical outcome was evaluated 1 year 
after the treatment. 
Results. Six patients survived: 5 in the DCE group (none of them was older than 60 years) and 
1 in the BMT group (P=0.03/0.06). Among survivors, none had a cerebral infarct volume of more 
than 390 cm3 (P=0.05). All survivors in the DCE group had favorable outcomes. There was no 
significant difference in the NIHSS and GCS scores between the groups and survivors/nonsurvi-
vors (P>0.05).
Conclusions. Decompressive surgery in the selected patients is likely to increase the probability 
of survival with a favorable outcome without increasing the number of severely disabled survivors. 
Patients with CIV of more than 390 cm3 may be bad candidates for DCE, and the prognosis is likely 
to be bad regardless the treatment strategy. The initial NIHHS and GCS scores did not prove any 
prognostic value in outcome.
Introduction
The management of ischemic stroke has im-
proved significantly over the past decades. Large 
multicentre trials and studies have shown many ev-
idence-based improvements in stroke care (such as 
intravenous thrombolysis, anticoagulants, antiplate-
let agents, etc.) successfully introduced and used on 
a daily basis. However, despite all advances, stroke 
care is still one of the most challenging tasks in neu-
rology and neurosurgery, and stroke remains the 
second most common cause of death worldwide (1).
There is a subdivision (up to 15%) of stroke pa-
tients (1–6) who deteriorate rapidly after hospital 
admission for cerebral infarction; when patients are 
treated conservatively, the treatment outcome is 
poor with a mortality rate reaching 80% (1, 2–4, 6, 
7), and survivors remain severely disabled (7). The 
involvement of the entire middle cerebral artery 
(MCA) territory produces the most devastating, 
massive hemispheric, space-occupying supratento-
rial infarct, which is known as a “malignant” MCA 
stroke. In such cases, most patients die within 1 
week (1–8) due to brain herniation caused by in-
farct-related, space-occupying edema.
Several medical therapies, including endotra-
cheal intubation, osmotherapy, barbiturates, ster-
oids, hyperventilation, and blood pressure control, 
have been proposed to reduce the development of 
brain edema and elevated intracranial pressure, but 
so far, they have not proven to reduce mortality or 
disability (1–7). Several reports suggest that these 
therapies can even be detrimental (6).
Due to limitations of medical therapies, decom-
pressive craniectomy (DCE) with duraplasty may 
ameliorate the effects of infarct-related edema and 
has been proposed as a surgical option for those ex-
periencing a large-volume MCA stroke. The proce-
dure has been known since the middle of the 20th 
century, but because of limitations in postopera-
522
Medicina (Kaunas) 2012;48(10)
tive critical care, it was rarely performed before the 
1990s. With many advances in postoperative critical 
care, there has been a resurgence of interest in DCE 
over the last 20 years. The rationale of this therapy is 
to create a compensatory space to accommodate the 
swollen brain, thus preventing the death spiral (vi-
cious circle of extensive edema and further infarc-
tion) and thereby normalizing intracranial pressure 
and restoring the midline position of the brain stem 
and the diencephalon.
By now, there is still limited evidence regarding 
the efficiency of DCE. The results of recently done 
randomized controlled trials (RCTs) – DECIMAL, 
DESTINY, and HAMLET – exploring the impact of 
early decompressive surgery on mortality and func-
tional outcome after malignant MCA stroke in a se-
lected population have clearly shown an increased 
probability of survival without an increase in the 
number of very severely disabled (modified Rankin 
Scale [mRS] of 5) survivors (2, 3). Whereas most cli-
nicians agree that the procedure is probably life-sav-
ing, the best indications for application of DCE are 
still far from clear, and the decision to perform DCE 
is still done on an individual basis in every patient. 
At the same time, cerebral infarct volume (CIV) as 
a triage criterion for performing surgery is not dis-
cussed in international literature. The team of neuro-
surgeons at Pauls Stradins Clinical University Hospi-
tal has initiated a prospective randomized controlled 
trial on decompressive craniotomies in the selected 
patients with a “malignant” MCA stroke. The aim of 
study was to investigate the value of CIV and the ini-
tial scores of the National Institutes of Health Stroke 
Scale (NIHHS) and the Glasgow Coma Scale (GCS) 
as the possible triage criteria in the surgical treatment 
of patients with a “malignant” MCA stroke.
Material and Methods
A sequential design-based, prospective, rand-
omized, controlled trial was carried out.
Twenty-eight patients were prospectively ana-
lyzed during the period 2009–2012. The inclusion 
criteria into the study were as follows: age of at least 
18 years of both sexes, major space-occupying cer-
ebral infarction of at least 50% of the MCA territory 
as defined by computed tomography (CT) and/or 
magnetic resonance imaging (MRI) with or with-
out additional infarction in the territory of the an-
terior or posterior cerebral artery on the same side, 
or cerebral infarct volume (CIV) of >145 cm3, with 
an acute onset of corresponding clinical signs and 
symptoms (NIHHS score, >15), and no absolute 
contraindications to perform DCE, and possibility 
to start surgery within 48 hours from onset. The 
exclusion criteria were as follows: the mRS score of 
2 or more before stroke and other serious prestroke 
conditions that could affect a clinical course, GCS 
score of 5 or less, 2 fixed dilated pupils, known co-
agulopathy or systemic bleeding disorder, and con-
traindication for anesthesia. Patients were randomly 
divided (one-by-one randomization of patients who 
fulfilled the inclusion criteria) either into the DCE 
plus best medical treatment group or the best medi-
cal treatment (BMT) alone group. A parenchymal 
ICP monitoring gauge was implanted only for those 
in the DCE group, who had no signs of a cerebral 
midline shift on scans to avoid performing DCE in 
case if fatal brain edema is not going to develop. 
Decompression was performed if there were signs of 
elevated intracranial pressure on scans and clinically 
or ICP was more than 25 mm Hg for more than 
1 hour despite the maximal conservative treatment. 
The NIHHS and GCS scores at time of surgery 
(DCE group) or at time of including into the trial 
(BMT group) were measured in every case. CIV was 
measured in every case on CT or MRI scans (no 
later than 3 hours before surgery [DCE]) or includ-
ing into the trial [BMT]) according to the formula 
0.5×A×B×C, where A is the largest diameter of the 
infarct and B is the largest perpendicular diameter. 
The third vertical diameter (C) was determined by 
summing the thicknesses of the slices in which the 
lesion was visible (9).
DCE of at least 12 cm in diameter was done by 
removing the parts of the frontal, parietal, temporal, 
and occipital squama with removal of additional tem-
poral bone so that the floor of the middle cerebral 
fossa could be reached. The wide durotomy was per-
formed, and a dural patch was placed into the inci-
sion to enlarge the intradural space. The skin flap was 
then sutured. The infarcted brain tissue was not re-
sected. Medical management was conducted in either 
a stroke unit or an intensive care unit (ICU) setting.
Clinical outcome was evaluated 1 year after the 
treatment and rated on the mRS and was classi-
fied as favorable (mRS score, 0–4) and unfavorable 
(mRS score, 5–6).
Data processing and statistical analysis were 
done by using the Statistical Package for the So-
cial Sciences (SPSS) program version 18.0 and the 
MS Excel 2007 software. A statistical comparison 
of groups was done, and the mean values were cal-
culated. Statistical significance was defined as a P 
value of less than 0.05. The chi-square, Fisher exact, 
and Student t tests were employed to check the sta-
tistical significance.
Results
A total of 28 patients with a malignant MCA 
stroke were included in the trial. The mean age of 
the patients was 61.5 years (range, 49 to 81 years); 
12 (43%) were women. Eleven patients underwent 
DCE; 13 patients were included in the BMT group.
Three patients underwent DCE surgery during 
the period of the study, but were not included in 
the trial due to a time frame violation (they were 
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operated on later than 100 hours from onset). None 
of them survived.
There was 1 patient who had a parenchymal ICP 
monitoring gauge implanted, but no signs of her-
niation or elevated intracranial pressure developed. 
Since initially the patient was included in the DCE 
group, but did not receive decompression surgery, 
he was observed separately from both groups.
The mean age of the patients in the DCE group 
was 57.2 years (range, 49 to 67 years) and in the BMT 
group was 65 years (range, 49 to 81) (P=0.02). The 
mean interval between infarction and surgery was 
21 hours (range, 8 to 36) in the DCE group, and the 
mean interval between infarction and inclusion into 
the trial was 19 hours (range, 6 to 34) in the BMT 
group. The mean NIHHS scores were 21.2 (range, 
16 to 28) and 20.8 (range from 17 to 24) in the 
DCE and BMT groups, respectively (P>0.05). The 
mean CIV in the DCE group was 366 cm3 (range, 
165 to 623) and 367 cm3 (range, 145 to 598) in the 
BMT group (P>0.05). There was no significant dif-
ference in the mean GCS score comparing the DCE 
and BMT groups (mean, 8.8; range, 6 to 12, versus 
mean 8.7; range, 7 to 12; P>0.05).
The overall survival rate in the DCE group was 
45.5% (n=5, none of the patients was older than 60 
years) and 7.69% in the BMT group (n=1) (2-tailed 
P=0.03 by the chi-square test without a Yates cor-
rection [χ2=4.531, df=1] and P=0.06 by the Fisher 
exact test). In both the groups, none of the patients 
with CIV of more 390 cm3 survived (3 patients in 
the DCE group and 6 in the BMT group) (P=0.05). 
In the subgroup of patients with CIV of 390 cm3 or 
less, the survival rate was 62.5% and 14.3% in the 
DCE (5 of 8) and BMT groups (1 of 7), respectively 
(P=0.1). 
There was no significant difference in the NIHSS 
and GCS scores between the groups and survivors/
nonsurvivors (P>0.05).
Outcome among the survivors in the DCE group 
was favorable in all cases (3 patients with a mRS 
score of 3 and 2 with a MRS score of 2). The only 
survived patient in the BMT group one year after 
ictus was moderate-to-severe disabled (mRS of 4).
The majority of nonsurvivors in the DCE group 
died from the typical complications of stroke (pneu-
monia, urinary tract infections, bedsores, pulmo-
nary embolism, etc.) (10), which were not directly 
related to brain herniation. The average length of 
life from onset to death was 26 days in the DCE 
group and 7.7 days in the BMT group with a statis-
tically significant difference (P=0.009).
Discussion
From nowadays internationally available litera-
ture focusing on surgical treatment of malignant 
MCA stroke (case series and published data from 
randomized controlled trials), it is well known that 
decompressive surgery in some patients can be ef-
fective in terms of both survival and quality of life 
(2–5). Despite the efforts made over the last decades 
in search of the best indications for decompressive 
surgery, the question whether DCE will be effec-
tive or not for a concrete patient is still far from 
being clear. The analysis of data from the recently 
done RCTs suggests that decompressive surgery 
increases the probability of survival to nearly 80% 
(2–4, 6) and increases the number of patients with 
a favorable functional outcome after a malignant 
MCA stroke, at least if they are aged 60 years or 
less, surgery was undertaken within 48 hours from 
stroke onset and patient had no significant coexist-
ing diseases (2, 3, 6). 
In our trial, the patients aged 60 years and more 
were also included, and the overall survival rate in the 
DCE group was much lower (45.5%) than in RCTs 
(nearly 80%). The benefit of surgery comparing with 
the best medical treatment in terms of survival in 
our trial appears to be statistically significant when 
the standard chi-square test is employed (P=0.03), 
but taking into account small sample size of our trial, 
the Fisher exact test (P=0.06) still highly suggests a 
benefit of surgery in selected patients. Nonetheless, 
the study is still ongoing, and hopefully, the benefit 
of surgery in selected patients will become statisti-
cally proven with more patients involved. 
Among the survivors in the DCE group, none 
was older than 60 years (the oldest survivor, 57 
years). The survival rate in the DCE subgroup of 
patients younger than 61 years was 62.5%. Slight-
ly worse results in the DCE subgroup of patients 
younger than 61 years can be possibly explained by 
a small number of patients involved. 
The difference in age between the groups is rec-
ognized as one of the weaknesses of this trial so far. 
Nonetheless, our results tend to agree with the pre-
vious findings from uncontrolled series suggesting 
that the age of more than 60 years is likely to be a 
predictor of bad outcome (5). Despite the fact that 
at the moment there is no evidence from RCTs ex-
ploring the impact of DCE on patients aged more 
than 60 years and age is most likely one of the most 
powerful predictors of bad outcome (several uncon-
trolled series demonstrated improved outcomes in 
patients aged 50 or 60 and less (5, 6), still there is 
no doubt that DCE can be useful also for very se-
lected patients older than 60 years if they are with-
out significant comorbidities that could limit their 
survival and/or rehabilitation potential. In general, 
the effectiveness of DCE in the elderly subpopula-
tion remains questionable, and more data from ran-
domized trials are needed to address this question 
in the future.
Two patients who did not underwent DCE sur-
vived: 1 patient initially assigned to the DCE group, 
who did not develop the signs of elevated intracranial 
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pressure or herniation, and a 72-year-old woman 
in the BMT group, and their survival can be eas-
ily explained by the fact that not every patient with 
an MCA infarct develops fatal brain edema (6, 11) 
and relatively small CIV (159 and 146 cm3), which 
is just a little above the widely accepted threshold 
of 145 cm3 to be considered as a “malignant” MCA 
stroke (2).
Data from internationally available literature 
indicate that the mortality rate after a “malignant” 
MCA stroke if treated only medically is about 80% 
(1–4, 6, 7, 12–14). In our trial, the mortality rate in 
the BMT group was even higher (92.31%), which 
actually in not controversial to the international 
data, but a slightly higher mortality rate in our study 
can be explained by a relatively small number of the 
patients included that does not allow us to make 
clear conclusions.
In internationally available literature, an MCA 
stroke is defined as “malignant” if CIV is 145 cm3 or 
more (2). CIV as an independent criterion whether 
to perform DCE or not is not discussed in litera-
ture. In our trial, we found that in both the groups, 
none of the patients survived with CIV of more than 
390 cm3. The P value of this finding (P=0.05) is 
of borderline significance and highly suggests that 
patients with CIV of >390 cm3 may be bad candi-
dates for DCE (they die due to complications that 
develop on the background of extremely devastat-
ing disease), and surgery done on them only leads 
to more pain and suffering. More data are needed to 
support this finding.
However, most of colleagues agree that mortality 
alone is not the only important issue; the concern 
is not only about survival, but also rather about a 
clinical outcome and quality of life. There is still 
ongoing discussion about the cutoff of mRS score 
to be used to distinguish “favorable” outcome from 
“unfavorable.” The answer to this question becomes 
even more difficult because our understanding of 
what patients view as an acceptable outcome may be 
poor. However, in most of the literature, a favora-
ble outcome is defined as survival without a disas-
trous outcome, e.g., complete dependency or per-
manent vegetative state (mRS score of 5) (1–3, 6). 
Data from RCTs showed that DCE in the selected 
patients increases the probability of survival with-
out increasing the number of very severely disabled 
survivors (2, 3, 6). Our findings support the inter-
national data – all the survivors in the DCE group 
had favorable outcomes.
Conclusions
Decompressive surgery in the selected patients 
is very likely to increase the probability of survival 
with a favorable outcome without increasing the 
number of severely disabled survivors. Patients with 
CIV of more than 390 cm3 may be bad candidates 
for DCE, and the prognosis is likely to be bad re-
gardless the treatment strategy. Initial NIHHS and 
GCS scores did not prove any prognostic value in 
outcome by now. More data from RCTs are needed 
to support these findings.  
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